Navigation Links
Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
Date:5/14/2008

SUNNYVALE, Calif., May 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it has filed a Schedule 14D-9 Solicitation/Recommendation Statement with the Securities and Exchange Commission (the "Commission"), as required by the Commission's rules, in response to an unsolicited tender offer (the "Offer") by RWD Acquisition I LLC (the "Purchaser") to purchase up to 4 million shares of the common stock of Pharmacyclics, Inc. (the "Company") for $1.05 per share. The terms and conditions of the Offer are set forth in an Offer to Purchase and the related Letter of Transmittal (collectively, the "Offer to Purchase") filed with the Commission by the Purchaser on May 1, 2008. Robert W. Duggan, one of the Company's principal stockholders and a member of the Company's board of directors (the "Board") is the sole member of Purchaser.

The Board is expressing no opinion to the Company's stockholders and is remaining neutral with respect to the Offer. The Board has not made a determination whether the Offer is fair to or in the best interests of the Company's stockholders and is not making a recommendation regarding whether the Company's stockholders should accept the Offer and tender their Shares, and if so how many shares to tender, or reject the Offer and not tender their Shares. The Company believes that a stockholder's decision on whether or not to tender shares in the Offer and, if so, how many shares to tender, is a personal investment decision based upon each individual stockholder's particular circumstances. The Company believes that each stockholder should review the Offer, consult with such holder's financial, tax and accounting advisors and make an independent determination.

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities of Pharmacyclics, Inc. Stockholders are advised to make their own decisions on whether to tender their shares and accept the Offer, based on all of the available information, including the factors considered by the Board. These factors are described in the Company's Schedule 14D-9, filed today with the Commission. The Schedule 14D-9 and the Offer to Purchase contain important information that should be read carefully before any decision is made with respect to the Offer. Stockholders can receive copies of such documents free of charge at the SEC's web site, http://www.sec.gov. The Purchaser has stated that copies of the Offer to Purchase will be made available at Purchaser's expense. Stockholders who wish to receive copies of the Offer to Purchase should contact MacKenzie Partners, Inc., the information agent for the Offer, collect at (212) 929-5500 or toll- free at (800) 322-2885. Stockholders may also obtain free copies of the Company's Schedule 14D-9 and other documents filed with the Commission by contacting Leiv Lea, Vice President, Finance and Administration and Chief Financial Officer and Secretary, in writing at 995 East Arques Avenue, Sunnyvale, California 94085 or by telephone at (408) 774-0330.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmacyclics Reports Third Quarter 2008 Financial Results
2. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
3. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
4. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
5. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
6. The Quantum Group Files Four Additional Patents
7. Phyhealth Files Historical Financials With the Pink Sheets and Takes Next Step Toward Becoming Fully Reporting
8. Laser Energetics Files Patent Application for a New BrightStar(TM) Alexandrite Laser
9. Penn Treaty Files 2006 Form 10-K
10. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
11. Conseco Files 10-K and Sets Earnings Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... 2017 , ... Functional imaging data supports improved cognition in ... today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , It ... improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et al., ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston dentist ... his office, Antoine Dental Center. Currently, patients can get single dental implants for ... but patients can learn more about these offers by contacting Antoine Dental Center. ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provost of Liberty University, has officially announced the appointment of Peter A. Bell, ... College of Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to ...
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Urinary Incontinence Drugs ... benchmarks in the global Urinary Incontinence market. The research answers ... key drugs marketed for Urinary Incontinence and their clinical attributes? How ...
(Date:2/23/2017)... Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... innovative proprietary products for the urology market, will release ... ended December 31, 2016 before the market open on ... will host a conference call and webcast to discuss ... 9, 2017 at 11:00 a.m. Eastern Time (10:00 a.m. ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... - 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs ... benchmarks in the global Oesophageal Cancer market. The research ... the key drugs marketed for Oesophageal Cancer and their clinical attributes? ...
Breaking Medicine Technology: